Xemperia SA develops blood tests and DNA‑based nanosensors for early detection and monitoring of cancer by analysing cancer-associated biomarkers in blood using immune-cell and nucleic‑acid approaches. Its activities include a PCR‑compatible breast cancer screening test undergoing larger-scale validation and nanosensor technologies initially targeted at research‑use applications.
AI-generated
Offering
Products & services
Industry:Medical Technology Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Blood test for early detection of breast cancer, prepared for a large-scale performance study; as a PCR kit for standard IVD qPCR instruments with an algorithm for data interpretation.
Nanosensors for nucleic acid detection
Nanosensors for research use for rapid, sensitive and precise detection of miRNAs and DNA mutations; clinical test development planned later.
Liquid biopsy solutions for cancer early detection and monitoring
Liquid biopsy solutions based on multiomics, immune cell signatures and DNA technologies for early detection, monitoring and therapy selection in cancer.
Knowledge
No knowledge articles yet
Once Xemperia SA has claimed this profile, we'll publish editorial articles and case studies here together.